Justin Balko, PharmD, PhD, explains why residual disease in triple-negative breast cancer signals a biology gap, and what ADC trials and cell-free DNA monitoring may reveal.
Justin Balko, PharmD, PhD
Advertisement
Articles by Justin Balko, PharmD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Health System Pharmacies Keep Patients on GLP-1 Therapy
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Melatonin Use Linked to Small REM Sleep Reduction in Children
4
Opposing Sides of 340B Debate Converge on Data Clearinghouse, Patient Definition
5